Previous 10 | Next 10 |
NovaBay press release (NYSE:NBY): Q1 GAAP EPS of $0.00 beats by $0.03. Revenue of $2.63M (+45.3% Y/Y) misses by $0.63M. For further details see: NovaBay GAAP EPS of $0.00 beats by $0.03, revenue of $2.63M misses by $0.63M
Avenova ® Spray unit sales increased 15% with record-high units sold through the OTC channel Announced launch of two next-generation OTC DERMAdoctor products this week building on momentum of top-selling collections, bringing new OTC product introductions to five si...
AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...
NovaBay Pharmaceuticals (NYSE:NBY) said it expanded its top-selling Kakadu C and Calm Cool + Corrected product lines by introducing new products with anti-aging ingredients to help reduce the appearance of wrinkles, fine lines, pores and discoloration. "We've expanded two highly popular skinc...
Next generation of popular skincare solutions combine anti-aging and brightening agents to help reduce the appearance of wrinkles, fine lines, pores and discoloration for normal and sensitive skin types NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a ph...
NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2022 after market close on Thursday, May 12, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. ...
Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm to be Featured on “Get Ready, Gorgeous with Ali” on April 12 at 8 a.m. Eastern Time NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a company developing and commercializing high-...
Soap-free and pH-balanced formula features jojoba seed and orange peel oils to gently lift away impurities and remove makeup without drying skin NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a pharmaceutical company developing and commercializing high-q...
NovaBay Pharma (NBY -2.2%) posted lower-than-expected Q4 revenue Net product revenue for the quarter rose 40% to $2.6 million, but missed estimates by $0.71M. The company recorded $1.6M from Avenova spray sales, $0.6M of DERMAdoctor product sales. The company's operating costs were ...
NovaBay Pharmaceuticals, Inc. (NBY) Q4 2021 Earnings Conference Call March 29, 2022 16:30 ET Company Participants Jody Cain - Investor Relations Justin Hall - Chief Executive Officer and General Counsel Andy Jones - Chief Financial Officer Conference Call Participants Destiny Hance - Ladenbur...
News, Short Squeeze, Breakout and More Instantly...
NovaBay Pharmaceuticals Inc. Company Name:
NBY Stock Symbol:
NYSE Market:
NovaBay Pharmaceuticals Inc. Website:
NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Ea...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports record sales of Avenova ® -branded eyecare products during the Amazon Prime Day event, which was held July 16-17, 2024. Over the two-day period, Avenova sales were 17% higher compared with Prime Day 2023 and were up 40% over ...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants, Series F-1 warrants, Series F-2 warrants and Series F-3 warrants f...